Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases.
FAIL · Does not pass the screen
83.92 USD
Screen close, 2026-10-01 · not a live quote Last reviewed 4 days ago
Screened 2026-10-01 · the tape above runs as of 13:03 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
What this means: price 83.92 against the desk's fair-value range, base estimate 138.50, over the last year.
Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical does not pass the values gate
Price83.92 USD
Fair value138.50
Ethical score70.0/100
Our investment reviews on this name
2026-10-02Read Markdown83.92+0.0% to today
2026-09-05Read Distribution98.08-14.4% to today ✓
2026-07-02Read Markup99.35-15.5% to today
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Mirum Pharmaceuticals, Inc. holds its Markdown at $83.92. Consolidating, no directional conviction, held for 14 days.
As held on the ledger · 2026-10-01
Phase
Markdown · caution
Quantitative state
Consolidating, no directional conviction, held for 14 days
Price at the screen
$83.92
Valuation
N/A trailing · -242.07 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.49
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
37.90%
Below 33%
Interest-bearing debt is 37.9% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
10.28%
Below 33%
Cash held in interest-bearing accounts and securities is 10.3% of assets, under the one-third limit.
Pass
Receivables
49.83%
Below 49%
Money owed to the company is 49.8% of assets, under the 49% limit.
Pass
Revenue purity
2.44%
Below 5%
Only 2.4% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Mirum Pharmaceuticals,'s business is in a permissible area, but its interest-bearing debt is about 38% of the company, just over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-10-04. It updates when the underlying figures move, and past reads are kept below.
Fair value range in USD, drawn from the 2026-10-01 screen. The gold marker is the market price at the same screen. A 65.0% margin of safety to the base estimate.
Third-party analyst targets: 14 covering, consensus Strong Buy. The average target sits +65% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-01 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Rare disease bets meet brutal cash losses
A patient in a small clinic finally gets access to a new therapy for a lifelong liver condition. That is the hopeful story Mirum tells with its lead drug. Yet the numbers show a company still deep in the red, with revenue growing fast but profits nowhere in sight.
We pass because forward earnings sit at a deeply negative multiple, margins run at minus 140 percent and return on equity is worse still. Strong analyst targets and clean ethical clearance do not change the fact that this remains a pre-profit business whose growth has yet to translate into sustainable returns.
The obvious risk is that high cash burn continues and dilution or delays push any breakeven further out. Cyclical funding markets for biotech can turn cold quickly when results disappoint. Analysis, not advice.
The risks · The things to watch: as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
MIRM trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-02Markdown · changed$83.92-14.4%Entry 6
The framework has shifted from distribution to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 14.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 18% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 92%. Our forward projection puts the odds of a 10% gain over the next month near 45%. The street (13 analysts) rates it strong buy, with a mean price target of $144.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 7.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 18% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 92%. Our forward projection puts the odds of a 10% gain over the next month near 45%. The street (13 analysts) rates it strong buy, with a mean price target of $144.
2026-08-05Markup$105.95+6.6%Entry 4
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 6.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 18% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 92%. Our forward projection puts the odds of a 10% gain over the next month near 45%. The street (13 analysts) rates it strong buy, with a mean price target of $144.
2026-07-18Markup$99.35+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 18% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 92%. Our forward projection puts the odds of a 10% gain over the next month near 45%. The street (13 analysts) rates it strong buy, with a mean price target of $144.
2026-07-03Markup$99.35+0.0%Entry 2
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
2026-07-02Markup$99.35Entry 1
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
